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NCL, genetics, mutationThe neuronal ceroid lipofuscinoses (NCLs) are a group of inherited neurodegenerative disorders that affect chil-
dren and adults and are grouped together by similar clinical features and the accumulation of autoﬂuorescent
storage material. More than a dozen genes containing over 430 mutations underlying human NCLs have been
identiﬁed. These genes encode lysosomal enzymes (CLN1, CLN2, CLN10, CLN13), a soluble lysosomal protein
(CLN5), a protein in the secretory pathway (CLN11), two cytoplasmic proteins that also peripherally associate
with membranes (CLN4, CLN14), and many transmembrane proteins with different subcellular locations
(CLN3, CLN6, CLN7, CLN8, CLN12). For most NCLs, the function of the causative gene has not been fully deﬁned.
Most of themutations in these genes are associatedwith a typical disease phenotype, but some result in variable
disease onset, severity, and progression, including distinct clinical phenotypes. There remain disease subgroups
with unknownmolecular genetic backgrounds. This article is part of a Special Issue entitled: “Current Research on
the Neuronal Ceroid Lipofuscinoses (Batten Disease).”
© 2015 Elsevier B.V. All rights reserved.The neuronal ceroid lipofuscinoses share common clinical features
that include epileptic seizures, progressive psychomotor decline, visual
failure, and premature death. NCL disease usually begins in childhood,
andmost types are inherited in an autosomal recessivemanner. Howev-
er, there are several types with onset in early to late adulthood, includ-
ing one type with autosomal dominant inheritance. Mutations in more
than a dozen genes have been described in families diagnosed with
NCL disease (Table 1). Those genes that cause the most prevalent and
typical NCL disease with onset in childhood have been identiﬁed.
There remain families diagnosed with NCL of all ages of onset in
which the underlying genetic cause has not been described. Thus far,
these cases do not appear to be caused by mutations in other genes
that cause NCL-like disease in animals.
The aim of this review is to brieﬂy summarize the genetic basis of
NCL and any correlations with disease phenotype. Details on mutations
can be found in the NCLmutation database (http://www.ucl.ac.uk/ncl).
NCL diseasewas ﬁrst divided into four broad ages of onset in the late
1960s: infantile, late infantile, juvenile, and adult, due to initial simple
supposition that there are four genes responsible for NCL disease:
CLN1, CLN2, CLN3, and CLN4, respectively. The ﬁrst genes to be identiﬁedPMR, Epilepsy with progressive
esearch on theNeuronal Ceroid
ecular Cell Biology, University
K. Tel.: +44 207 679 7257;were in the most common subtypes (CLN1, CLN2, CLN3). However, it
was many years, with several further genes identiﬁed in less common
forms of NCL, before a gene encoding the rare dominant adult type
was found (CLN4). A variety of experimental approaches, largely reﬂec-
tive of the available technology at the time of identiﬁcation, were used
to identify genes causing NCL (Table 1). The ﬁrst genes were discovered
in 1995 following classic and time-consuming genetic linkage ap-
proaches using large numbers of similarly affected families followed
by positional cloning of the genes (CLN1/PPT1 and CLN3). In contrast, a
biochemical approach that detected a missing mannose-6-phosphate
tagged lysosomal enzyme in a patient allowed the identiﬁcation of
CLN2/TPP1. The nextwave of gene identiﬁcation required fewer families
to provide sufﬁcient power for genetic linkage analysis, due to the com-
pletion of the sequence of the human genome that providedmore infor-
mative sequence variants (CLN5, CLN6, CLN7/MFSD8, CLN8). Several of
these genes were identiﬁed by narrowing the candidate gene region
by recognition of the stretches of homozygosity in consanguineous fam-
ilies. Recent improvements in sequencing technology that permit mas-
sively parallel sequencing of thewhole exome in a relatively short space
of time have allowed identiﬁcation of the disease gene even in single
families (CLN4/DNAJC5, CLN11/GRN, CLN12/ATP13A2, CLN13/CTSF,
CLN14/KCTD7).
All NCL genes lie on autosomes, and in most cases, disease is
inherited in a recessive manner, where deleterious mutations are pres-
ent in both disease gene alleles. There are two notable exceptions:
(1) adult onset NCL caused bymutations in CLN4/DNAJC5 is dominantly
inherited in all families described [1]; (2) there is one published report
of uniparental disomy in the NCLs in which a patient with complete
Table 1
Summary of the identiﬁcation of genes that cause NCL.
Gene Year of identiﬁcation Main approaches used for locus identiﬁcation Other approaches used Reference
CLN1/PPT1 1995 Linkage Linkage disequilibrium [31]
CLN2/TPP1 1997 Biochemical Linkage [32]
CLN3 1995 Linkage Linkage disequilibrium [33]
CLN4/DNAJC5 2011 Linkage, exome sequencing Gene expression [1]
CLN5 1998 Linkage Linkage disequilibrium [34]
CLN6 2002 Linkage Homozygosity mapping [35]
CLN7/MFSD8 2007 Linkage Homozygosity mapping [36]
CLN8 1999 Linkage, animal model Homozygosity mapping [8]
CLN9 Not known
CLN10/CTSD 2006 Animal model [37,38]
CLN11/GRN 2012 Linkage, exome sequencing [10]
CLN12/ATP13A2 2012 Exome sequencing [21]
CLN13/CTSF 2012 Linkage, exome sequencing [39]
CLN14/KCTD7 2012 Exome sequencing [17]
2238 S.E. Mole, S.L. Cotman / Biochimica et Biophysica Acta 1852 (2015) 2237–2241isodisomy of chromosome 8, leading to homozygosity of a maternally
inherited deletion in CLN8, is described [2].
The majority of NCL genes encode proteins that reside in the
secretory and/or endo/lysosomal pathways. In most cases, these are
lysosomal proteins, which include enzymes and a soluble protein
(encoded by CLN1/PPT1, CLN2/TPP1, CLN5, CLN10/CTSD, CLN13/CTSF)
and transmembrane proteins (encoded by CLN3, CLN6, CLN7/MFSD8,
CLN12/ATP13A2). However, the transmembrane proteins CLN6 and
CLN8 both localize to the endoplasmic reticulum (ER), and progranulin,
encoded by CLN11/GRN, is demonstrated to reside in compartments in
the secretory pathway [3]. Two other NCL proteins, encoded by CLN4/
DNAJC5 andCLN14/KCTD7, are both cytoplasmic and peripherally associ-
ated with cellular membranes. The in vivo substrates for the soluble ly-
sosomal enzymes are incompletely deﬁned, and knowledge regarding
the primary functions of themembrane proteins in these compartments
largely remains unresolved.
For the enzymatic deﬁciencies, enzyme replacement and gene ther-
apy are promising approaches that are actively undergoing clinical
development [4]. However, the unresolved functions for the other NCL
proteins, which are less compatible with gene/protein replacement ap-
proaches, remain problematic for targeted therapy development. It is
unclear which cellular defects due to their loss of function are primary
versus secondary, and which of these defects play a central role in the
cellular dysfunction and death that ensues. Despite these gaps in under-
standing of NCL protein function, there is wide evidence to indicate that
cellular processes involving lipid and protein trafﬁcking in the endocytic
pathway and the regulation of endosomal and lysosomal transport are
points of convergence for a number of the NCL protein deﬁciencies. A
detailed overview of the current understanding of function for each of
the NCL-encoded proteins can be found in this special issue [5].
For most NCL genes, there is a typical disease phenotype associated
with complete loss of function. However, for many, there are also phe-
notypes recognized as NCL that are more protracted or have a later
age of onset (Table 2). These arise frommutations that have ‘milder’ ef-
fects on gene function, and these phenotypes can vary quite consider-
ably. For example, classic CLN6 disease begins in early childhood, but
disease onset can be delayed until adulthood, with no associated visual
failure [6]. There is also clinically similar NCL disease arising frommuta-
tions inmore than onegene (e.g. late infantile variant NCL can be caused
bymutations in CLN5, CLN6, CLN7, or CLN8). This led to the development
of a new classiﬁcation system that is gene based and takes into account
these marked phenotypic consequences [7].
There are an increasing number of examples of different mutations
in a single gene giving rise to quite different diseases (Table 2): (1) A
recessive missense mutation in CLN8 [8] causes progressive epilepsy
with mental retardation (EPMR). This disease is an intellectual
developmental disorder that presents with seizures in the juvenile age
range that cease at adulthood and was the ﬁrst genetic disease to be
recognized for CLN8. Mutations that cause a more typical NCL weredescribed later. (2) A particular missense mutation in CLN2/TPP1 is as-
sociated with spinocerebellar ataxia SCAR7, a slowly progressing but
not life-limiting disease with no ophthalmologic abnormalities or epi-
lepsy, and absence of typical storage [9]; A homozygous recessivemuta-
tion in GRN that is associated with rectilinear proﬁles, as found in
progranulin-deﬁcient mice [10], leads to CLN11 disease, whereas het-
erozygous mutations are a major cause of frontotemporal lobar degen-
eration with TDP-43 inclusions (FTLD-TDP), the second most common
type of early-onset dementia. In this NCL family, it seems that carriers
of this mutation are at risk of developing dementia with increasing
age, which had beenmasked by the early death of many oldermembers
on both sides of the family. The age-at-onset and neuropathology of
FTLD-TDP and NCL are markedly different and exemplify genetic links
that have been emerging between rare diseases and common neurolog-
ical disorders, such as Niemann–Pick C disease with Alzheimer's disease
[11] and type 1 Gaucher disease with Parkinson's disease [12]. (3) Evi-
dence suggests that the most common and very widespread mutation
in CLN3, a 1-kb deletion, does not completely abolish CLN3 function,
suggesting that disease caused by complete loss of function has not
yet been recognized or may be lethal [13]; other recently described dis-
tinct phenotypes associated with CLN3 mutations include retinitis
pigmentosa without other clinical symptoms, even in mid-late adult-
hood [14] and a distinct disease described as autophagic myopathy as-
sociated with heart failure [15], considerably extending the phenotype
of CLN3-associated disease. (4) There are also reports of other families
with mutations in NCL genes that have predominantly visual prob-
lems [16]. (5) The only autosomal dominant type of NCL is CLN4 disease.
Disease caused by complete loss of CLN4 function is not known,
although animal models would predict very severe and early-onset
disease. (6) Mutations in CLN14/KCTD7 have now been reported to
cause three different diseases, including NCL-like CLN14 disease
[17–20]. (7) One family has been diagnosed with CLN12 disease, an
atypical NCL [21], whereas all other mutations in ATP13A2 cause
Kufor–Rakeb syndrome. (8) One mutation in SGSH was described in a
case diagnosedwith adult onset NCL.Mutations in this gene usually un-
derlie late infantile onset disease mucopolysaccharidosis type IIIA
(MPSIIIA) [22].
Mutations in NCL genes range from those that are described in one
or only a few families, to those that are more common in certain popu-
lations due to local founder effects. Several NCL genes have widespread
distribution across several continents due to ancient founder effects
(Table 2). The common mutation causing juvenile CLN3 disease is the
best example of this, though it is unclear whether this global spreading
provided a genetic advantage in the past. Diagnostic testing can be ap-
propriately targeted to these common mutations.
There are reports of patients carrying changes in more than one NCL
gene. One that was later found to be compound heterozygous for muta-
tions in CLN5 also carries a single mutation in the CLCN6 gene. Another
family has been described in which a single mutation in CLCN6 is the
Table 2
Correlation between genotype and phenotype in NCL cases.
Gene No.
mutations
Widespread common mutations Country-speciﬁc mutations Genotype-phenotype correlationa
CTSD/CLN10 8 Not known Not known Congenital
Late infantile
Juvenile
Adult
PPT1/CLN1 67 p.Arg122Trp
p.Arg151*
p.Thr75Pro and
p.Leu10* in Scotland
Infantile
Late infantile
Juvenile
Adult
TPP1/CLN2 116 c.509-1GNC
p.Arg208*
p.Glu284Val in Canada Late infantile
Juvenile
Protracted
SCAR7
CLN3 67 1 kb intragenic deletion in
Caucasian populations
1 kb deletion in many countries
2.8 kb intragenic deletion in Finland
Juvenile
Protracted
Autophagic vacuolar myopathy
Retinitis pigmentosa
Cone-rod dystrophy
CLN5 36 None p.Tyr392* and
p.Trp75* in Finland
Late infantile
Juvenile
Protracted
Adult
CLN6 71 None p.Ile154del in Portugal Late infantile
Protracted
Adult Kufs type A
Juvenile cerebellar ataxia
Teenage progressive myoclonic epilepsy
MFSD8/CLN7 38 None P.Thr294Lys in Roma Gypsies;
c.724+2TNA in Eastern Europe
Late infantile
Juvenile protracted
Macular dystrophy
Cone-rod dystrophy
CLN8 31 None p.Arg24Gly in Finland causing EPMR
p.Arg204Cys and p.Trp263Cys in Turkey
Late infantile
Protracted
EPMR/Northern epilepsy
CLN4/DNAJC5 2 p.Leu116del
p.Leu115Arg
N/A Adult autosomal dominant (Parry disease)
CLN11/GRN 2b N/A N/A Adult
Frontotemporal lobar dementia (when heterozygous)
CLN12/ATP13A2 1c N/A N/A Juvenile
Kufor–Rakeb syndrome
CLN13/CTSF 6 N/A N/A Adult Kufs type B
CLN14/KCTD7 1d N/A N/A Infantile
Progressive myoclonic epilepsy-3
Opsoclonus-myoclonus ataxia-like syndrome
SGSH 2e N/A N/A Adult
Late infantile MPSIIIA
CLCN6 2f Not known Not known Adult (only found in heterozygous form to date)
a Bold – phenotype caused by complete loss of gene function. Italics – non-NCL disease phenotype that in some cases may be more typically associated with this gene.
b Only themutation that causes NCLwhenpresent on both disease alleles is indicated; thismutation, and othermutations in this gene, cause later onset frontotemploral lobar dementia
when present in heterozygous form.
c Only the mutation that causes NCL is indicated; other mutations cause Kufor–Rakeb syndrome.
d Only the mutation that causes NCL is indicated; other mutations cause PME-3 or opsoclonus-myoclonus ataxia-like syndrome.
e Only the mutations described in a patient diagnosed with NCL are indicated; all other known mutations cause MPSIIIA.
f These mutations in CLCN6may modify disease phenotype.
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tion is present but not identiﬁed, as the CLCN6 carrier parents in both
families were not affected, and a mouse model lacking CLCN6 clearly
has an NCL-like disease. Some patients carry mutations in more than
one gene that underlie variant late infantile NCL (e.g. themutation data-
base lists changes in CLN5 that have been found alongside those in CLN6
or CLN7 or CLN8). Thesemay be examples of amutation or speciﬁc allele
of one gene enhancing or ameliorating the NCL disease phenotype.
There are also several reports that implicate NCL genes in awider bi-
ology of disease: (1) Combinations of mutations may cause a markedly
modiﬁed disease course, such as a patient with disease that presented
shortly after birth who was found to carry heterozygous mutations in
CLN5, together with a mutation in POLG1 that acts to maintain mito-
chondrial DNA integrity [23]. (2) Increased expression of CLN8 may
act as a modiﬁer of Gaucher disease [24]. (3) Somatic mutations in all
known NCL genes are acquired in human cancer cells (COSMIC)and may confer a growth advantage (CLN1/PPT1, CLN2/TPP1,
CLN3, CLN4/DNAJC5, CLN5, CLN6, CLN7/MFSD8, CLN8, CLN10/CTSD,
CLN11/GRN, CLN12/ATP13A2, CLN13/CTSF, CLN14/KCTD7, as well as
SGSH and CLCN6) (http://www.sanger.ac.uk/genetics/CGP/cosmic/)
[25]. Further correlations may be revealed with the increasing
number of sequence variations that are being described by large-
scale genome sequencing projects (e.g. Exome Aggregation Consor-
tium (ExAC): http://exac.broadinstitute.org).
It is likely that some patients diagnosed with NCL may really have
atypical forms of other diseases. However, a distinction between disease
phenotypes may not be as clear cut as originally thought. Advances in
DNA sequencing technology are likely to lead to the identiﬁcation of
the disease gene causing any atypical disease. It may be timely to review
the criteria that deﬁne the NCL family of diseases. This could be consid-
ered by a recognized group of experts at the next international congress
to be held in 2016, following the working pattern already established
Table 3
Summary of mutation and sequence variants in NCL genes contained within the NCL Mutation Database (May 2015).
Gene CLN1 CLN2 CLN3 CLN4 CLN5 CLN6 CLN7 CLN8 CLN10 CLN11 CLN12 CLN13 CLN14 Grand total
Total changes 76 140 80 2 46 75 40 33 13 2 1 6 1 515
Mutations 67 116 67 2 36 71 38 31 8 2 1 6 1 446
Sequence variations 9 24 13 – 10 4 2 2 5 – – – – 69
Missense 29 53 19 1 16 38 21 20 6 0 1 4 1 209
Nonsense 11 16 14 – 8 9 7 1 1 1 – – – 68
Small deletions 7 14 9 1 8 9 1 5 1 1 – – – 56
Small insertion or duplication 5 8 6 – 3 4 – – – – – 1 – 27
Splice defects 11 17 15 – – 6 8 1 4 – – 1 – 63
Large deletions 1 1 4 – 1 1 – 4 0 – – – – 12
Large insertions – – – – – – – – – – – – – 0
Delins 1 2 – – – 3 1 – – – – – – 7
Promoter change 3 4 2 – – 2 – – – – – – – 11
3′ UTR changes 2 1 – – – – – – – – – – – 3
Initiation site change 1 – – – – – – – – – – – – 1
No. of patients 220 369 423 7 89 132 91 74 15 3 4 7 2 1436
No. of families 167 347 396 7 81 112 73 69 11 2 1 4 1 1271
Only data that cause NCL are included (see Table 2)
Small deletions/insertions are b 100 b. Large deletions/insertion are N 100 b.
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ease nomenclature for the NCLs.
It can be predicted from observations in mouse or other animal
models that mutations in some genes cause disease that is similar to
NCL even though the disease described in humans so far is not similar.
For example, CLCN7 underlies the severe autosomal recessive disease
infantile malignant osteopetrosis, and when the osteopetrosis is treated
with bonemarrow transplantation, patients go on to develop blindness
and CNS degeneration, suggesting that speciﬁc mutations or alleles in
this gene may cause NCL-like disease. Intriguingly, recent evidence in
cattle indicates that mutations in CLCN7 also underlie severe gingival
hamartomas and osteopetrosis, with evidence suggestingNCL-like lyso-
somal storage is present in these animals [26].
The NCL Mutation Database (http://www.ucl.ac.uk/ncl) lists all mu-
tations and sequence variations in NCL genes. 446 NCL disease-causing
mutations are currently listed (Table 3). This mutation database in-
cludes the genetic basis of NCL disease in all patients and families
(N1270) reported in clinical or scientiﬁc publications or by personal
communication to the curator to allow better correlation between
gene changes and disease phenotype. An estimate of the proportion of
cases caused by eachmutation can bemade, although there is an under-
representation of the occurrence of the most common mutations since
diagnostic laboratories generally publish or submit novel mutations
only to the database. 69 sequence variants that have been found in the
course of sequencing NCL genes diagnostically are also listed in this da-
tabase. Correlations between genotype, phenotype, and morphological
changes in patients have been reviewed previously [27,28]. It is impor-
tant to know these correlations as new treatments that do not fully
compensate for the genetic defectmay reduce but not completely elim-
inate the disease burden.
The number of families with NCL that remain unsolved at the DNA
level used to be estimated at 10% of cases. This must be decreasing
due to the advances in DNA sequencing technology being applied both
to current and to historical samples and to comprehensive genetic diag-
noses becomingmore widely available. The exact number of genes that
can cause NCL remains uncertain. At least one family thought to repre-
sent CLN9, and associated with disease of juvenile onset, and speciﬁc
cell characteristics, is now reclassiﬁed as a CLN5 variant [29]. However,
the genetic basis in at least one other similar family has yet to be clari-
ﬁed [30]. The most recently identiﬁed genes are found only in single
families, and while there is no disputing that these novel genes cause
disease, it may be timely to revisit the criteria for a diagnosis of NCL.
The new gene-based classiﬁcation scheme for the NCLs [7] links with
the most recent diagnostic algorithms that take into account these
rare as well as more common genetic bases for NCL.In conclusion, the expanding numbers of NCL genes combined with
the recognition of the broader range of associated phenotypes is con-
tributing to a fuller understanding of the molecular genetics of NCL.
This genetic picture is considerably more complex than was ﬁrst
envisioned at the start of the genetic era of the NCLs.
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